CTOs on the Move

Diassess

www.diassess.com

 
Diassess Inc. is revolutionizing the way infectious diseases are prevented, diagnosed, and monitored by developing the tools necessary to empower people to become knowledgeable about their health.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Diassess raised $21.9M on 07/17/2018

Similar Companies

Scientia Advisors

Scientia Advisors is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Exscientia

Exscientia is a global pharmatech company using patient-first artificial intelligence (AI) to discover better drugs, faster. Our mission is to encode, automate and transform every stage of the drug design and development process, by combining the latest AI techniques with experimental innovation, to enable the design of patient centric drug candidates with an improved probability of success. Our validated platform has delivered the first three AI-designed drugs to enter clinical trials and is the first AI system proven to improve clinical outcomes in oncology. We`ve significantly accelerated pre-clinical drug discovery, with 10x productivity improvement in delivering a drug candidate compared with industry standards. By actively applying AI to precision engineer medicines more rapidly and efficiently, we allow the best ideas of science to rapidly become the best medicines for patients.

NCG Medical Systems

NCG Medical Systems is a Altamonte Springs, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Exagen Diagnostics

Exagen Diagnostics, Inc. is committed to providing excellent service to our physicians, patients and partners.

Insmed

Insmed is a global biopharmaceutical company focused on the needs of patients with rare diseases. Headquartered in Bridgewater, NJ, Insmed is a dynamic and rapidly growing company with a strong pipeline of drug candidates. At Insmed, we are on a mission to transform the lives of patients battling serious rare diseases. We are developing novel, targeted therapies to help serve the critical unmet needs of these patients. In concert with developing therapeutic solutions, we are committed to improving the entire patient experience. “Insmed is a team of talented and motivated professionals who are dedicated to making a difference in the lives of patients with rare diseases, said Will Lewis, president and CEO at Insmed.